Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers

Get an expert’s take on the evolving role of immune checkpoint inhibitors in managing advanced gastric and esophageal cancers with this CME-certified program, which features a series of ClinicalThought™ commentaries on emerging clinical data, managing immune-related adverse events, and key biomarkers of response.
Steven Maron, MD

ClinicalThought

Gain expert insight on the use of ICIs either as monotherapy or in combination with targeted agents when managing patients with gastric or GEJ cancer, as informed by recent data from the 2019 Gastrointestinal Cancers Symposium.

Steven Maron, MD Released: February 26, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Tina B. Stacy, PharmD, BCOP, CHCP
(404) 425-4474
tstacy@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?